Needham & Company Affirms Acadia Pharma (ACAD) at 'Buy'; Says Initial Nuplazid Sales Affected by Sampling
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Needham & Company affirms Acadia Pharma (Nasdaq: ACAD) at Buy with a price target of $49 following Q2 results on Thursday night.
Analyst Alan Carr commented today,
Acadia reported $97,000 in Nuplazid 2Q16 sales, compared to our $0.5M and consensus $0.1M estimates. Mgmt reported that extensive use of sampling programs significantly impacted sales. We expect this to continue into 3Q16 and have adjusted our estimates for 2016 accordingly. Nevertheless, mgmt reported positive anecdotal response from physicians and caregivers and noted launch is meeting internal expectations. Nuplazid was launched 5/31/16 for the treatment of Parkinson's Disease Psychosis (PDP). Our peak U.S. sales estimate in PDP is unchanged (up to ~$1B). Mgmt guided for top-line results from Phase 2 Alzheimer's Disease Psychosis (ADP) trial in 4Q16 (unch). A positive outcome may subsequently drive off-label use in this and several other dementia-related psychoses.
The company has called on 9,700 of target 12,000 physicians since launch. Medicare Part D plans are expected to complete formulary process by 90 days post-launch. Formulary process at private payers is expected to be completed by early 2017. Mgmt expects prior authorization to be most common restriction. To-date, most pts are Medicare Part D. Time to fill script is around 5-10 days.
Acadia previously announced a delay in planned 2Q16 MAA submission of Nuplazid due to EMA rejection of Pediatric Investigation Plan. Acadia had initially sought a waiver, but the EMA indicated a plan is still necessary. Mgmt guided for submission of a new plan in 3Q16. We believe an MAA could be submitted in early 2017, Carr noted.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Finisar (FNSR) PT Raised to $44 at Needham & Company, Estimates Raised Sharply
- Broadcom (AVGO) PT Raised to $215 at Oppenheimer
- Argus Downgrades Abercrombie & Fitch (ANF) to Sell
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesNeedham & Company, Alan Carr
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!